{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:34:37Z","timestamp":1761503677145,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.yebeh.2020.107072","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T13:16:20Z","timestamp":1586351780000},"page":"107072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impact of the EMA\/FDA alerts on the use of effective contraceptive method in women of childbearing age undergoing valproic acid treatment in a long-stay psychiatric center"],"prefix":"10.1016","volume":"107","author":[{"given":"Mar\u00eda","family":"Puig-Molto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Pol-Yanguas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1665-0860","authenticated-orcid":false,"given":"Blanca","family":"Lumbreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107072_bb0005","first-page":"92","article-title":"Use of valproic acid in long stay units of psychiatry","volume":"39","author":"Mart\u00ednez-Lazcano","year":"2015","journal-title":"Farm Hosp"},{"key":"10.1016\/j.yebeh.2020.107072_bb0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1471-244X-13-234","article-title":"Teratogenic risk and contraceptive counselling in psychiatric practice: analysis of anticonvulsant therapy","volume":"13","author":"Langan","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.yebeh.2020.107072_bb0015","doi-asserted-by":"crossref","first-page":"e3343","DOI":"10.1136\/bmj.e3343","article-title":"Abbott pays $1.6bn for promoting off label use of valproic acid","volume":"344","author":"Roehr","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2020.107072_bb0020","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.mayocp.2012.04.017","article-title":"Ten common questions (and their answers) about off-label drug use","volume":"87","author":"Wittich","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.yebeh.2020.107072_bb0025","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(80)91159-9","article-title":"Teratogenic potential of valproic acid","volume":"1","author":"Brown","year":"1980","journal-title":"Lancet."},{"author":"European Medicines Agency","key":"10.1016\/j.yebeh.2020.107072_bb0030"},{"year":"2018","series-title":"MHRA guide for healthcare professionals. Information on the risks of valproate (epilim, depakote, convyulex, episenta, epival, kentlim, orlept, sodium valproate, syonell & valpal) use in girls (of any age) and women of childbearing potential","author":"Medicines and Healthcare Products Regulatory Agency","key":"10.1016\/j.yebeh.2020.107072_bb0035"},{"key":"10.1016\/j.yebeh.2020.107072_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.seizure.2019.07.001","article-title":"Valproate utilisation trends among girls and women from 2013 to 2018","volume":"70","author":"Puteikis","year":"2019","journal-title":"Seizure."},{"key":"10.1016\/j.yebeh.2020.107072_bb0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/epi4.12228","article-title":"Valproic acid utilization among girls and women in Stockholm: impact of regulatory restrictions","volume":"3","author":"Karlsson Lind","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2020.107072_bb0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.yebeh.2020.107072_bb0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jfprhc-2013-100704","article-title":"Contraceptive and sexual health care issues in women with schizophrenia","volume":"39","author":"Oliver","year":"2013","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.yebeh.2020.107072_bb0060","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/schbul\/23.4.623","article-title":"Sexuality, reproduction, and family planning in women with schizophrenia","volume":"23","author":"Miller","year":"1997","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.yebeh.2020.107072_bb0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.pra.0000400263.52913.dc","article-title":"Prescribing contraceptives for women with schizophrenia","volume":"17","author":"Seeman","year":"2011","journal-title":"J Psychiatr Pract"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020302511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020302511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:30:58Z","timestamp":1761503458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020302511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":13,"alternative-id":["S1525505020302511"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107072","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the EMA\/FDA alerts on the use of effective contraceptive method in women of childbearing age undergoing valproic acid treatment in a long-stay psychiatric center","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107072"}}